Regimen Reference Order – BRST – gemcitabine + PACLitaxel

ARIA: BRST - [gemcitabine + PACLitaxel]

Planned Course: Every 21 days until disease progression or unacceptable toxicity
Indication for Use: Breast Cancer Metastatic or Recurrent

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L

- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – gemcitabine + PACLitaxel

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Day 1		
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes **1 hour** prior to PACLitaxel **Nursing Alert: PACLitaxel starts **1 hour after completion** of dexamethasone infusion*
Wait 1 hour after completion of IV pre-medication(s) before starting PACLitaxel		
PACLitaxel	175 mg/m^2	IV in normal saline 500 mL over 3 hours, following the administration rates below: • Administer at 100 mL/hour for 15 minutes, then • Administer remaining volume over 2 hours and 45 minutes *Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter* **Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug*
gemcitabine	1250 mg/m^2	IV in normal saline 250 mL over 30 minutes
Day 8		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
gemcitabine	1250 mg/m^2	IV in normal saline 250 mL over 30 minutes

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles
Day 1

- CBC and biochemistry as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period required after PACLitaxel. Patient can be discharged from treatment room if stable whether they had a reaction or not

Day 8

- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- PACLitaxel may cause progressive, irreversible neuropathy